Acorda Therapeutics Inc

Most Recent

  • uploads///Acor
    Company & Industry Overviews

    Who Is Eyeing Acorda Therapeutics?

    On October 3, Acorda Therapeutics had a consensus 12-month target price of $22.89, which represents an ~18.11% return on investment over the next 12 months.

    By Daniel Collins
  • uploads///Part
    Company & Industry Overviews

    Mylan’s Recently Launched Generic Version of Ampyra

    On September 21, Mylan (MYL) launched its authorized generic version of Acorda Therapeutics’ Ampyra, which is used for improvement in walking for adults who have multiple sclerosis.

    By Sarah Collins
  • uploads///dna _
    Company & Industry Overviews

    Why Axovant Sciences Stock Is Soaring

    Between March 31 and June 8, Axovant Sciences (AXON) stock rose ~284% from $1.69 to $4.80.

    By Margaret Patrick
  • uploads///pills _
    Company & Industry Overviews

    Analysts’ Ratings for Enanta Pharmaceuticals and Peers in April

    Of the four analysts covering Enanta Pharmaceuticals, one analyst gave the stock a “buy” rating and three analysts gave it a “hold.”

    By Kenneth Smith
  • uploads///ACOR_
    Company & Industry Overviews

    Exploring Acorda Therapeutics’ Financial Performance

    In fiscal 2017, Acorda Therapeutics (ACOR) generated total revenue of $588.2 million, compared with $519.6 million in fiscal 2016.

    By Kenneth Smith
  • uploads///ACOR
    Company & Industry Overviews

    Why Acorda Therapeutics is Focused on Inbrija

    Acorda Therapeutics (ACOR) generated $543 million from Ampyra sales in fiscal 2017.

    By Kenneth Smith
  • uploads///thermometer _
    Company & Industry Overviews

    Analysts’ Ratings for FibroGen and Its Peers in April 2018

    Of the seven analysts covering FibroGen in April, five have given the stock “strong buy” ratings, while two have given it “hold” ratings.

    By Kenneth Smith
  • uploads///ALKS
    Company & Industry Overviews

    A Look at Alkermes’ Diabetes Product Portfolio

    According to Alkermes, ~26.0 million people in the US and 382.0 million people globally are affected by diabetes.

    By Kenneth Smith
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.